期刊文献+

碳酸镧在维持性血液透析患者高磷血症中的应用研究 被引量:17

Study on application of lanthanum carbonate in maintenance hemodialysis patients with hyperphosphatemia
下载PDF
导出
摘要 目的探讨碳酸镧对伴有高磷血症的维持性血液透析(maintenance hemodialysis,MHD)患者磷酸盐代谢、微炎症、血脂及营养状态的影响。方法 80例伴有高磷血症的MHD患者随机分为碳酸镧组和碳酸钙组各40例,治疗12周。比较两组患者治疗前后磷酸盐代谢、微炎症、血脂及营养状态相关指标变化。结果在第12周末碳酸镧组皮肤瘙痒评分、血钙、磷、钙磷乘积、成纤维细胞生长因子23(fibroblast growth factor 23,FGF23)较基线显著下降(P<0.05),1,25二羟基维生素D[1,25-Dihydroxy vitamin D,1,25(OH)_2D]较基线显著升高,并与碳酸钙组相比有显著变化(P<0.05);碳酸钙组第12周末血钙及钙磷乘积与基线相比显著升高(P<0.05),而血磷、FGF23、1,25(OH)_2D无显著变化。结论碳酸镧能显著降低血磷、FGF23,使1,25(OH)_2D升高,而全段甲状旁腺激素(intact.parathyroid hormone,iPTH)、血清25羟维生素D[25-hydroxyvitamin D,25(OH)D]、血脂、微炎症及营养状态未受影响。 To explore the effects of lanthanum carbonate on phosphate metabolism, micro inflammation, blood lipids and nutritional status of MHD with hyperphosphatemia. Method 80 cases of MHD with hyperphos- phatemia from Beijing Chaoyang hospital were randomly divided into calcium carbonate group and lanthanum carbonate group with 40 cases in each group, which were all treatment for 12 weeks. The index' s changing of phosphate metabolism, micro inflammation, blood lipids and nutritional status of two groups before and after treatment were compared. Result At the end of the twelfth week, comparing with baseline, the skin pruritus score, the level of serum calcium and serum phosphorus, calcium phosphorus product and FGF23 were decreased significantly (P 〈 0.05 ) , the levels of sermn 1,25 (OH)2 O was increased significantly and had significant changes compared to calcium carbonate group(P〈0.05 ). The levels of serum calcium and calcium phosphorus product in ealcium carbonate group were increased significantly compared to baseline at the end of the twelfth week, but its levels of serum phos- phate, FGF23 and 1,25 (OH)2D were not changed significantly( P〈0.05 ). Conclusion Lanthanum carbonate can significantly reduce the levels of serum phosphate and FGF23, and increase the levels of serum 1,25 (OH)2 D, but it cannot affect the level of iPTH ,25 ( OH)D, micro inflammation and serum lipid.
出处 《中国医刊》 CAS 2015年第2期50-52,共3页 Chinese Journal of Medicine
关键词 肾透析 高磷血症 碳酸镧 Maintenance hemo dialysis Hyperphosphatemia Lanthanum carbonate
  • 相关文献

参考文献11

  • 1Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis [ J]. JAMA,2011,305( 11 ) :1119-1127.
  • 2Daugirdas JT, William FF, Emmett M, et al. The phosphate binder equivalent dose[J]. Semin Dial,2011,24( l ) :41-49.
  • 3Takeuchi K, Matsuda E, Sekino M, et al. Three-year follow-up of lanthanum carbonate therapy in hemodiatysis patients [ J ]. Ther Apher Dial,2013,17(4) :15-21.
  • 4Zhang C, Wen J, Li Z, et al. Efficacy and safety of lanthanum car- bonate on chronic kidney disease-mineral and bone disorder in dialy- sis patients: a systematic review [ J ]. BMC Nephrology, 2013,17 (10) :226-234.
  • 5Dellanna F, Reichel H, Seibt F. Efficacy and safety of lanthanum carbonate in German patients on dialysis[ J] Clin Nephrol,2012,78 (5) :382-390.
  • 6Ota S, Hirose M, Izumiya Y, et al. Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabol- ic turnover[ J ]. Ther Apher Dial ,2013,4 ( 17 ) :49-53.
  • 7Isakova T, Guti6rrez OM, Smith K, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease[ J]. Nephrol Dial Transplant,2011,26(2) :584-591.
  • 8蔡根深.不同透析膜在血液透析患者中透析效果的比较[J].中国医刊,2013,48(5):22-24. 被引量:7
  • 9Shigematsu T, Negi S, COLC Research Group. Combined therapy with lanthanum carbonate and calcimn carbonate for hyperphos- phatemia decreases serum FGF-23 level independently of calcium and PTH (COLC study) [ J]. Nephrol Dial Transplant,2012,27 (3) :1050-1054.
  • 10Manabe R, Fukami K, Ando R, et al. Effects of switching from cal- cium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients [ J ]. Ther Apher Dial,2013,17 (4) :35-40.

二级参考文献19

共引文献6

同被引文献155

  • 1陈少金,陈锦生,邱杰华,伍敏宜,廖彬容.高通量血液透析联合血液透析滤过治疗尿毒症血透患者皮肤瘙痒的临床效果[J].慢性病学杂志,2020(7):1119-1122. 被引量:8
  • 2刘蕾.营养护理干预对预防维持性血透患者高磷血症的效果研究[J].世界最新医学信息文摘,2019,0(103):360-361. 被引量:3
  • 3邓伟谦.对比血液透析滤过和血液灌流联合血液透析对尿毒症患者血清钙磷及甲状旁腺激素清除效果的影响[J].中国急救医学,2018,38(S02):114-114. 被引量:13
  • 4Tomayko EJ,Cachia AJ,Chung HR,et al.Resveratrol supplementation reduces aortic atherosclerosis and calcification and attenuates loss of aerobic capacity in a mouse model of uremia[J].J Med Food,2014,17(2):278-283.
  • 5Mcintire KL,Chen Y,Sood S,et al.Acute uremia suppresses leucine-induced signal transduction in skeletal muscle[J].Kidney Int,2014,85(2):374-382.
  • 6Thomson BK,Huang SH,Chan C,et al.Nocturnal home hemodialysis associates with improvement of electrocardiographic features linked to sudden cardiac death[J].ASAIO J,2014,60(1):99-105.
  • 7Mohlenkamp S, Moebus S, Sehmermund A, et al. Assesnent of the natuial history of ooronary artery calcification and identifica,tion of itS determinants[J]. Rationale of the 2rid part of the Heinz Nixdorf Recall Study. Herz,2007,32(2): 108-120.
  • 8Lynch K E, Lynch R, Curhan G C, et al. Prescibed dietary phos- phate restriction and survivon among hemodialysis patients [J]. Clin J Am Soc Nephorl,2010,6(3):620-629.
  • 9Savica V, Calo L A, Santoro D, et al. Salivary glands a new player in phosphorus metabolism[J].J Ren Nutr,2011,21(2):39-42.
  • 10Daugirds J T, Chertow G M, Larive B, et al. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder [J].J Am Soc Nephrol,2012,23(3):727-738.

引证文献17

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部